Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

H3K4me3, H3K27ac, EZH2 in K562

ABSTRACT: ChIP-seq of K562 cells: H3K4me3, H3K27ac, EZH2

PROVIDER: PRJEB72776 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12721580_1.fastq.gz	Fastqsanger.gz
	ERR12721580_2.fastq.gz	Fastqsanger.gz
	ERR12721581_1.fastq.gz	Fastqsanger.gz
	ERR12721581_2.fastq.gz	Fastqsanger.gz
	ERR12721582_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

H3K4me3 and H3K27ac ChIp-seq

Project description:H3K4me3 and H3K27ac ChIp-seq

| PRJNA512869 | ENA

ChIP-seq of H3K4me3 and H3K27ac of dermal fibroblasts

Project description:ChIP-seq of H3K4me3 and H3K27ac of dermal fibroblasts

| PRJEB22016 | ENA

Full proteome analysis of WT and Ezh2-KO K562 cells

Project description:Chemotherapy resistance is the main impediment in the treatment of acute myeloid leukaemia (AML). Despite rapid advances, the various mechanisms that lead to resistance development remain to be defined in detail. Here we report that loss-of-function mutations (LOF) in the histone methyltransferase EZH2 have the potential to confer resistance against the chemotherapeutic agent cytarabine. We identify seven distinct EZH2 mutations leading to loss of H3K27 trimethylation via multiple mechanisms. Analysis of matched diagnosis and relapse samples reveal a heterogenous regulation of EZH2 and a loss of EZH2 in 50% of patients. We confirm that loss of EZH2 induces resistance against cytarabine in the cell lines HEK293T and K562 as well as in a patient-derived xenograft (PDX) model. Proteomics and transcriptomics analysis reveal that resistance is conferred by upregulation of multiple direct and indirect EZH2 target genes that are involved in apoptosis evasion, augmentation of proliferation and alteration of transmembrane transporter function. Our data indicates, that loss of EZH2 results in upregulation of its target genes, providing the cell with a selective growth advantage, which mediates chemotherapy resistance.

2021-03-12 | PXD023139 | Pride

ChIP-seq of QSER1-FLAG, TET1-V5, DNMT3A, DNMT3B, EZH2, BCOR, H3K4me3, H3K27me3, H3K36me2, H3K36me3, H3K27ac, and H3K4me1.

Project description:ChIP-seq of QSER1-FLAG, TET1-V5, DNMT3A, DNMT3B, EZH2, BCOR, H3K4me3, H3K27me3, H3K36me2, H3K36me3, H3K27ac, and H3K4me1.

| PRJNA715662 | ENA

Skeletal muscle myonuclei-specific ChIP-Seq of H3K4me3 and H3K27ac

Project description:Skeletal muscle myonuclei-specific ChIP-Seq of H3K4me3 and H3K27ac

| PRJNA757393 | ENA

H3K27ac, H3K4me3 ChIPseq of A549 (T/T) and A549 (C/C) cells

Project description:Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) for histone modifications, H3K27ac, H3K4me3 in A549 (T/T) and A549 (C/C) cells;

2023-05-10 | GSE225332 | GEO

An Ezh2 and Ezh1 dual inhibitor, UNC1999, re-shapes the landscape of H3K27me3 versus H3K27ac in MLL-AF9-transformed murine leukemia

Project description:Ezh2 and EZH1 are histone H3 lysine 27 (H3K27)-specific methyltransferases. Their hyperactive mutations and overexpression were found in cancer including various hematological malignancies. UNC1999 is a highly selective inhibitor for both enzymes. It suppresses H3K27 tri- and di-methylation globally and inhibits growth of MLL-rearranged acute leukemia. Here we performed ChIP-Seq to profile how UNC1999 affects distribution of H3K27me3 and its antagonizing H3K27ac in MLL-AF9-immortalized leukemia cells. We also performed ChIP-seq of SUZ12, an essential common cofactor of EZH2 and EZH1 following compound treatments. We treated MLL-AF9 transformed murine leukemia cells with DMSO, UNC1999 or UNC2400 (an inactive analog compound of UNC1999). Cells were then collected and used for ChIP-Sequencing of Input, H3K27me3, SUZ12, and H3K27ac.

2014-10-30 | E-GEOD-62437 | biostudies-arrayexpress

Chip-seq of H3K4me3, H3K4me1, H3K27ac and P300 in HCC cells

Project description:Considered as fundamental epigenetic regulators controlling many key cellular processes, histone modifications are a well-conserved and widely studied class of epigenetic modifications. Genome-wide studies have identified enhancers as DNA sequences that bind to H3K4me1 and H3K27ac and promoters as DNA sequences that bind to H3K4me3. To explore how the Twist1 complex (Twist1/YY1/p300) regulates miR-9 expression, we performed ChIP-seq in PLC-PRF-5 cells, providing a panorama of p300, H3K4me3, H3K4me1, and H3K27ac.

2022-07-21 | GSE208334 | GEO

ChIP-seq of H3K27ac and H3K4me3 in HAP1 tRNA gene locus modified clones and control clones

Project description:This dataset contains ChIP-seq data profiling genomic binding of H3K27ac and H3K4me3 in single cell-derived control, as well as CRISPR/Cas9 induced tRNA gene deletion clones and intergenic region deletion clones in human cancer cell lines HAP1. In this study, we found a large genomic deletion of 10q23 in Cas9 modified clones and further investigate the effect of H3K27ac binding.

2023-10-24 | E-MTAB-11859 | biostudies-arrayexpress

Effects of vitamin D on histone modifications H3K27ac and H3K4me3 in THP-1 cells

Project description:Three independent repeats of ChIP-seq from THP-1 after 24h treatment with 1,25D or EtOH (control), using antibodies against histone markers H3K27ac and H3K4me3

2018-07-01 | GSE107851 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data